Gemcitabine treatment of experimental C6 glioma: The effects on cell cycle and apoptotic rate

Anticancer Research

Volumn 26, Issue 4 B, 2006, Pages 3017-3024

  Carpinelli, Giulia ^a   Bucci, Barbara ^b   D'Agnano, Igea ^c   Canese, Rossella ^a   Caroli, Fabrizio ^d   Raus, Laura ^d   Brunetti, Ercole ^b   Giannarelli, Diana ^d   Podo, Franca ^a   Carapella, Carmine M ^d  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Apoptosis; C6 glioma; Cell cycle; Gemcitabine; Malignant glioma; MRI

Indexed keywords

GEMCITABINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; FLOW CYTOMETRY; GLIOMA; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; TUMOR GROWTH;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BRAIN NEOPLASMS; CELL CYCLE; DEOXYCYTIDINE; GLIOMA; MAGNETIC RESONANCE IMAGING; MALE; RATS; RATS, WISTAR;

EID: 33746768801     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D and Rugg TA: Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 12: 1535-1540, 1994.
2. Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J and Melemed A: Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 62: 2-8, 2002.
3. Burris HA 3rd, Moore MJ, Andersen J et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997.
4. Carmichael J, Possinger K, Phillip P et al: Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 13: 2731-2736, 1995.
5. Possinger K, Kaufmann M, Coleman R et al: Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs 10: 155-162, 1999.
6. Trodella L, Granone P, Valente S et al: Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non-small-cell lung cancer. J Clin Oncol 20: 804-810, 2002.
7. van der Maase H: Gemcitabine in advanced bladder cancer. Semin Oncol 28: 11-14, 2001.
8. Wolff RA, Evans DB, Gravel DM et al: Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 7: 2246-2253, 2001.
9. Hertel LW, Boder GB, Kroin JS et al: Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). Cancer Res 50: 4417-4422, 1990.
10. Ostruszka LJ and Shewach DS: The role of DNA synthesis inhibition in the cytotoxicity of 2',2'-difluoro-2'-deoxycytidine. Cancer Chemother Pharmacol 52: 325-332, 2003.
11. Plunkett W, Huang P and Gandhi V: Preclinical characteristics of gemcitabine. Anticancer Drugs 6(Suppl 6): 7-13, 1995.
12. Lawrence TS, Eisbruch A, McGinn CJ, Fields MT and Shewach DS: Radiosensitization by gemcitabine. Oncology (Huntingt) 13(Suppl 5): 55-60, 1999.
13. Lawrence TS, Davis MA, Hough A and Rehemtulla A: The role of apoptosis in 2',2'-difluoro-2'- deoxycytidine (gemcitabine)-mediated radiosensitization. Clin Cancer Res 7: 314-319, 2001.
14. Mason KA, Milas L, Hunter NR et al: Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int J Radiat Oncol Biol Phys 44: 1125-1135, 1999.
15. Milas L, Fujii T, Hunter N et al: Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 59: 107-114, 1999.
16. Mose S, Class R, Weber H, Rahn A, Brady LW and Böttcher HD: Radiation enhancement by gemcitabine-mediated cell cycle modulations. Am J Clin Oncol 26: 60-69, 2003.
17. Ostruszka LJ and Shewach DS: The role of cell cycle progression in radiosensitization by 2',2'-difluoro-2'-deoxycytidine. Cancer Res 60: 6080-6088, 2000.
18. Pauwels B, Korst AE, Pattyn GG et al: Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro. Int J Radiat Oncol Biol Phys 57: 1075-1083, 2003.
19. Morgan MA, Parsels LA, Parsels JD, Mesiwala AK, Maybaum J and Lawrence TS: Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine. Cancer Res 65: 6835-6842, 2005
20. Cappella P, Tomasoni D, Faretta M et al: Cell cycle effects of gemcitabine. Int J Cancer 93: 401-408, 2001.
21. Rieger J, Durka S, Streffer J, Dichgans J and Weller M: Gemcitabine cytotoxicity of human malignant glioma cells; modulation by antioxidants, BCL-2 and dexamethasone. Eur J Pharmacol 565: 301-308, 1999.
22. Gertler SZ, MacDonald D, Goodyear M et al: NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94). Ann Oncol 11: 315-318, 2000.
23. Wick W, Hermisson M, Kortmann RD et al: Neoadjuvant gemcitabine/ treosulfan chemotherapy for newly diagnosed glioblastoma. J Neuro-Oncol 59: 151-155, 2002.
24. Maraveyas A, Sgouros J, Upadhyay S, Abdel-Hamid AH, Holmes M and Lind M: Gemcitabine twice weekly as a radiosensitiser for the treatment of brain metastases in patients with carcinoma: a phase I study. Br J Cancer 92: 815-819, 2005.
25. kip1 levels. Oncogene 20: 2814-2825, 2001.
26. D'Agnano I, Antonelli A, Bucci B et al: Effects of poly (ADP-ribose) polymerase inhibition on cell death and chromosome damage induced by VP16 and Bleomycin. Environ Mol Mutagenesis 32: 56-63, 1998.
27. Crowley J (ed.). Handbook of Statistics in Clinical Oncology. New York, Marcel Dekker, 2001.
28. Evelhoch JL, Gillies RJ, Karczmar GS et al: Applications of magnetic resonance in model systems: cancer therapeutics. Neoplasia 2: 152-165, 2000.
29. San-Galli F, Vrignaud P, Robert J, Coindre JM and Cohadon F: Assessment of the experimental model of transplanted C6 glioblastoma in Wistar rats. J Neuro-Oncol 7: 299-304, 1989.
30. Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 559: 1011-1018, 2002.
31. Walker MD, Green SB, Byar DP et al: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303: 1323-1329, 1980.
32. Azria D, Jacot W, Prost P et al: Gemcitabine and ionizing radiations: radiosensitization or radio-chemotherapy combination. Bull Cancer 89: 369-379, 2002.
33. Braakhuis BJ, Ruiz van Haperen VW, Boven E, Veerman G and Peters GJ: Schedule-dependent antitumor effect of gemcitabine in in vivo model system. Semin Oncol 22(Suppl 11): 42-46, 1995.